Patents by Inventor Bryan W. King

Bryan W. King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20230120185
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: September 27, 2022
    Publication date: April 20, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Heterocyclic amides as kinase inhibitors
    Patent number: 11485710
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: November 1, 2022
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Modulators of stimulator of interferon genes (STING)
    Patent number: 11377440
    Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: July 5, 2022
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David T. Fosbenner, Todd L. Graybill, Jianxing Kang, Bryan W. King, Yunfeng Lan, Lara Kathryn Leister, Mukesh K. Mahajan, John F. Mehlmann, Angel I. Morales-Ramos, George Scott Pesiridis, Joshi M. Ramanjulu, Joseph J. Romano, Stuart Paul Romeril, Mark J. Schulz, Huiqiang Zhou, Junya Qu
  • Heterocyclic Amides as Kinase Inhibitors
    Publication number: 20210253532
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10899716
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: January 26, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)
    Publication number: 20200291001
    Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Inventors: David T. FOSBENNER, Todd L. GRAYBILL, Jianxing KANG, Bryan W. KING, Yunfeng LAN, Lara Kathryn LEISTER, Mukesh K. MAHAJAN, John F. MEHLMANN, Angel I. MORALES-RAMOS, George Scott PESIRIDIS, Joshi M. RAMANJULU, Joseph J. ROMANO, Stuart Paul ROMERIL, Mark J. SCHULZ, Huiqiang ZHOU, Junya QU
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20200165205
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Niall Andrew ANDERSON, Deepak BANDYOPADHYAY, Alain Claude-Marie DAUGAN, Frederic G. DONCHE, Patrick M. EIDAM, Nicolas Eric FAUCHER, Nicolas S. GEORGE, Philip Anthony HARRIS, Jae U. JEONG, Bryan W. KING, Clark A. SEHON, Gemma Victoria WHITE, David Duff WISNOSKI
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10590085
    Abstract: Disclosed are compounds having the formula (I): wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20180134665
    Abstract: Disclosed are compounds having the formula (I): wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 17, 2018
    Inventors: Niall Andrew ANDERSON, Deepak BANDYOPADHYAY, Alain Claude-Marie DAUGAN, Frederic G. DONCHE, Patrick M. EIDAM, Nicolas Eric FAUCHER, Nicolas S. GEORGE, Philip Anthony HARRIS, Jae U. JEONG, Bryan W. KING, Clark A. SEHON, Gemma Victoria WHITE, David Duff WISNOSKI
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160122342
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Inventors: David T. FOSBENNER, Bryan W. KING, Steven David KNIGHT, Louis Vincent LaFRANCE, III, Mei LI, Kenneth C. McNULTY, Stuart Paul ROMERIL, Mark Andrew SEEFELD
  • AMINO-QUINOLINES AS KINASE INHIBITORS
    Publication number: 20160060222
    Abstract: Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: November 6, 2015
    Publication date: March 3, 2016
    Inventors: Michael Jonathan BURY, Linda N. CASILLAS, Adam Kenneth CHARNLEY, Michael P. DeMARTINO, Xiaoyang DONG, Patrick EIDAM, Pamela A. HAILE, Philip Anthony HARRIS, Ami Lakdawala SHAH, Bryan W. KING, Robert W. MARQUIS, JR., John F. MEHLMANN, Joseph J. ROMANO, Clark A. SEHON
  • AMINO-QUINOLINES AS KINASE INHIBITORS
    Publication number: 20130053375
    Abstract: Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: May 6, 2011
    Publication date: February 28, 2013
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam Kenneth Charnley, Michael P. DeMartino, Xiaoyang Dong, Patrick Eidam, Pamela A. Haile, Philip Anthony Harris, Ami Lakdawala Shah, Bryan W. King, Robert W. Marquis, JR., John F. Mehlmann, Joseph J. Romano, Clark A. Sehon
  • IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
    Publication number: 20130018039
    Abstract: Disclosed are compounds having the formula: wherein R1A, R1B, R2 and R3 are defined herein, and methods of making and using the same.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 17, 2013
    Inventors: Vera Q. Bodmer, Linda N. Casillas, Michael P. DeMartino, Philip A. Harris, Bryan W. King, Ami Lakdawala Shah, Lara Kathryn Leister, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Matthew A. Wilson, David Duff Wisnoski
  • Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7122560
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, B, R1, R2, U, X, Y, Z, Ua, Xa, Ya, and Za are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), and/or TNF-? converting enzyme (TACE), or a combination thereof.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Bryan W. King
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7074810
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: July 11, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Cyclic sulfonyl compounds as inhibitors of metalloproteases
    Patent number: 6927216
    Abstract: The present application describes novel cyclic sulfonyl derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: August 9, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert J. Cherney, Bryan W. King
  • Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040266751
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: June 16, 2004
    Publication date: December 30, 2004
    Inventor: Bryan W. King
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040116491
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: October 3, 2003
    Publication date: June 17, 2004
    Inventors: Bryan W. King, James Sheppeck, John L. Gilmore
  • Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040072802
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: October 9, 2002
    Publication date: April 15, 2004
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Mathew E. Voss
  • &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6495565
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: December 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Jr., Matthew E. Voss